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1. Introduction 
The HL-A antigens used for most of the biochemi- 
cal studies in the past have been solubilized from 
cellular materials. However in such cases the recovery 
of purified active molecules is always low, no matter 
which solubilization technique is used. 
Accordingly. a richer and/or more abundant 
source of HL-A antigens which can easily be purified 
had to be sought. Two recent publications have report- 
ed such sources: Billing and Terasaki [l] showed that 
large quantities of HL-A antigens are present in human 
serum, and Robert et al. [2] were able to demonstrate 
the presence of HL-A antigens in the urine of patients 
suffering from tubular proteinuria. 
Since urine is abundant and easy to collect, we 
have partially purified HL-A antigens from that of 
diseased and of normal individuals. 
2. Materials and methods 
The urine was provided by donors whose HL-A 
specificities had been phenotyped. Antigenic activity 
in the urines was monitored by either the lymphocy- 
totoxicity inhibition test [3] or the complement 
fixation inhibition test [4]. The urines were purified: 
a) by filtration on Sephadex G-75, G-100 and G-200 
in 0.05 M TrissHCl , 0.15 M NaCl buffer, pH 7.3; 
b) by chromatography on DEAE-Sephadex A-50 in 
0.05 M TrissHCl , 0.05 M NaCl buffer, pH 8.0. The 
active molecules were eluted after a continuous gra- 
dient was applied: 0.3 M NaCl, mixing chamber of 
200 ml; c) by preparative polyacrylamide gel elec- 
trophoresis (pH 9.4, 7% acrylamide for the separating 
gel, 4% acrylamide for the stacking gel), using a 
Canalco apparatus (PD-2/ 150 column). Analytical 
polyacrylamide gel electrophoresis of the purified 
active fractions was carried out in SDS containing 
systems [5] and at pH 9.4. Proteins were determined 
by the Folin procedure of Lowry et al. [6] in con- 
centrated and dialysed fractions (Diaflo-membranes, 
UM-20, AMICON). 
3. Results and discussion 
Urine from several diseased and healthy individuals 
were tested for the presence of HL-A antigens (table 
1). 
It should be noted that the specificity ratio (SR) 
in the crude urines tested was very low in each case 
and simple filtration on Sephadex did not improve 
the ratio. However, DEAE-Sephadex chromatography 
enabled a great number of proteins which interfered 
with the serological tests to be eliminated, for all the 
HLA specificities tested after elution from the column 
had a much higher SR (# 6). 
3.1. Urine from diseased individuals 
Fig. 1 shows the elution profile after ion-exchange 
chromatography. The two HL-A specificities tested 
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Table 1 
Characterization of HL-A specificities in the urine of diseased and healthy individuals 
Source of urine Phenotype HL-A HL-A specificities Protein Total ID50 Specific activity Specificity 
tested (mg/l)* (IV/l) (IU/mg protein) ratio (SR)** 
Cystinosis D.F. HL-Al, HL-A 3, HL-A 1, HL-A 3 300 15.000 50 2 
W 14, W 27. 
Cystinosis G.G. HLA 2, HL-A 3, HLA 2, HL-A 3, 570 16.000 28 2 
HLA 7, -. HLA 7. 
Cystinosis V.T. HLA 2, HLA 5, HL-A 2, HL-A 5. 360 50.000 140 2 
W 32, W 27. 
Wilson disease M.T. HLA 2, HLA 12, HL-A 2 400 64.000 160 2 
W 29, W 27. 
normal urine A.D. HLA 1, HL-A 9, HL-A 1, HL-A 9 100 14.000 140 2 
HL-A 8, -. (HL-A 9) 
* Proteins were determined on 1 litre samples concentrated to 4 ml on Diaflo-membranes, UM-20. 
** Specificity ratio = ratio of 1 I.U. (= ID,, = 50% inhibition dose) determined in a non specific system, to 1 I.U. deter- 
mined in a specific system. 
TUBE NUMBER 
Fig. 1. Chromatography on DEAE-Scphadex A-50 (70 X 2 cm). Sample: 3 liters urine (cystinosis, V.T.), concentrated to 12 ml on 
Diaflo-membrane UM-20 and dialysed against column buffer (0.05 M Tris-HCl, 0.05 M NaCl, pH 8.0). 3 ml fractions were col- 
lected. Application of continuous gradient (0.3 M NaCl, mixing chamber of 200 ml) at fraction 110. The protein elution pattern 
was determined at 280 nm on 0.1 ml aliquots from each fraction. The inhibitory activity was tested for HL-A2 (- - - - - ) and for 
HLAS (. . . . .) 
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Fig. 2. Preparative polyacrylamide gel electrophoresis of an active fraction eluted from DEAE-Sephadex A-SO (fraction 238 from 
fig. 1). 4 ml separating el (7% acrylamide, pH 9.4), 2 ml stacking gel (4% acrylamide, pH 6.7). Electrode buffer: 0.05 M Tris, 0.4 M 
glycine, pH 8.9; elution buffer: 0.3 M Tris-HCl, pH 8.9. Pre-run until elution of bromophenol blue marker. Electrophoresis at 
100 V; 6 mA. 1.5 ml fractions. Elution of HL-A2 activity in fractions 64 and 65 (5.000 LU.). 
were partially separated. The most active fractions 
were separately submitted to further purification by 
preparative polyacrylamide gel electrophoresis at pH 
9.4. HL-A specificities in a small area could always be 
seen (fig. 2). Fig. 3 shows the analytical gels of a 
purified active fraction. Electrophoresis at pH 9.4 
gave rise to a single band (stained with amidoblack 
and with periodic acid-Schiff reagent [7], whereas 
the active fractions eluted from DEAE-Sephadex all 
contained several protein bands in the same condi- 
tions. After electrophoresis in the presence of SDS, 
the single band was divided into three constituents 
of approximately 40 000, 70 000 and 80 000 mol. wt. 
It should be emphasised that neither the active 
fractions purified on DEAE-Sephadex, nor the active 
fractions obtained after purification by polyacrylamide 
gel electrophoresis contained beta-2-microglobulin. 
This may be because of our techniques, but Robert 
et al. [2] made a similar observation. They were 
able to demonstrate by serological tests that most 
of the /3-2-microglobulin was separated from the HL-A 
molecule during purification on DEAE-Sephadex. 
310 
3.2. Urine from healthy individuals 
The preliminary results obtained from the study 
of normal urine can be resumed as follows: only HL- 
A 9 with an SR of 2 could be characterized in the 
crude urine, while other HLA specificities could not 
be detected. Billing and Terasaki [l] have already 
noted this behaviour of HL-A 9 during their studies 
on human serum. However, after purification on 
DEAE-Sephadex, the active molecules appeared more 
monospecific (SR # 6). This was the case for all the 
specificities detected in the donor, not only for HL-A9. 
The active molecules in normal urine had the same 
DEAE-Sephadex and preparative polyacrylamide gel 
electrophoresis elution profiles as those purified 
from the urine of diseased individuals. 
When the serological activity of the fractions that 
have been partially purified from urine and that of 
extracts solubilized from cell membranes is compared, 
the former appears very low. However, it is possible 
that the HL-A antigens excreted in urine have under- 
gone some form of inactivation and that in urine the 
serological activity detected comes from many more 
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Fig. 3. Analytical SDS a&amide gels of the active fraction 
64 (fig. 2) A. Amido black stained gel. B. Periodic acid- 
Schiff stained gel. 
protein than is the case for HLA molecules solubilized 
from cell membranes. 
We shall try to determine the activity/protein ratio 
by further purification of the active molecules, prefer- 
ably using normal urine which is more abundant and 
easily available. 
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